SEC Form 4 · accession 0001104659-18-006230
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven P. Gelone
Officer — Chief Scientific Officer
Period of report
Jan 31, 2018
Accepted (ET)
Feb 2, 2018 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1,F2 | — | Jan 31, 2018 | A | 100,000 | A | — | Jan 31, 2028 | Ordinary Shares | 100,000 | 100,000 | D |
| Restricted Stock UnitsF3,F4 | — | Jan 31, 2018 | A | 22,500 | A | — | Jan 31, 2021 | Ordinary Shares | 22,500 | 22,500 | D |
Explanation of responses
- F1The exercise price is $6.47 per share.
- F2The option award was granted on January 31, 2018. Vesting began on January 31, 2018 and ends on January 31, 2022. Twenty-five percent (25%) of the option award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period.
- F3The restricted stock units shall convert into ordinary shares on a one-for-one basis upon vesting of the units.
- F4Vesting of the restricted stock unit award is subject to U.S. Food and Drug Administration ("FDA") approval of a new drug application ("NDA") for lefamulin. Fifty percent (50%) of the restricted stock unit award will vest upon FDA approval of an NDA for lefamulin, and the remaining fifty percent (50%) of the restricted stock unit award will vest on the one (1) year anniversary of such approval. If the FDA does not approve an NDA for lefamulin within two years of the grant date, the the restricted stock unit award will terminate in full.